BNP Paribas Financial Markets’s Lexeo Therapeutics LXEO Stock Holding History

BNP Paribas Financial Markets’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.81M	Buy	388,398 +160,197	+70%	+$867K	﹤0.01%	2873
2026 Q1	$1.31M	Sell	228,201 -29,216	-11%	-$207K	﹤0.01%	2952
2025 Q4	$2.56M	Buy	257,417 +226,690	+738%	+$2.07M	﹤0.01%	2469
2025 Q3	$204K	Sell	30,727 -17,707	-37%	-$85.6K	﹤0.01%	4004
2025 Q2	$195K	Buy	48,434 +8,223	+20%	+$27K	﹤0.01%	3777
2025 Q1	$140K	Buy	40,211 +5,684	+16%	+$25.2K	﹤0.01%	3902
2024 Q4	$227K	Buy	34,527 +28,986	+523%	+$228K	﹤0.01%	3793
2024 Q3	$50.1K	Buy	5,541 +3,591	+184%	+$42.8K	﹤0.01%	3612
2024 Q2	$31.3K	Sell	1,950 -2,831	-59%	-$41.1K	﹤0.01%	3571
2024 Q1	$75K	Buy	+4,781	New	+$74.8K	﹤0.01%	3504

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BNP Paribas Financial Markets's LXEO Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Lexeo Therapeutics (LXEO) stake by 70% in Q2 2026, buying an estimated $867K and bringing the position to 388,398 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2873.

BNP Paribas Financial Markets first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.56M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

BNP Paribas Financial Markets held 388,398 shares of Lexeo Therapeutics worth $1.81M as of Q2 2026.
BNP Paribas Financial Markets bought 160,197 Lexeo Therapeutics shares in Q2 2026, an estimated $867K.
Lexeo Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2873 holding.
BNP Paribas Financial Markets first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
BNP Paribas Financial Markets's Lexeo Therapeutics position peaked at $2.56M in Q4 2025.
141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.